Login / Signup

Primary biliary cholangitis: Epidemiology, prognosis, and treatment.

Juan P TrivellaBinu V JohnCynthia Levy
Published in: Hepatology communications (2023)
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. The incidence and prevalence of PBC vary widely in different regions and time periods, and although disproportionally more common among White non-Hispanic females, contemporary data show a higher prevalence in males and racial minorities than previously described. Outcomes largely depend on early recognition of the disease and prompt institution of treatment, which, in turn, are directly influenced by provider bias and socioeconomic factors. Ursodeoxycholic acid remains the initial treatment of choice for PBC, with obeticholic acid and fibrates (off-label therapy) reserved as add-on therapy for the management of inadequate responders or those with ursodeoxycholic acid intolerance. Novel and repurposed drugs are currently at different stages of clinical development not only for the treatment of PBC but also for its symptomatic management. Here, we summarize the most up-to-date data regarding the epidemiology, prognosis, and treatment of PBC, providing clinically useful information for its holistic management.
Keyphrases
  • risk factors
  • type diabetes
  • primary care
  • healthcare
  • electronic health record
  • machine learning
  • deep learning
  • ulcerative colitis
  • glycemic control
  • sensitive detection
  • decision making
  • african american
  • living cells